… This review focuses on erlotinib in advanced stage NSCLC, but the drug is also being
investigated in earlier stages of disease. An ongoing adjuvant trial, RADIANT, is open world-wide …

… In contrast, increasing severity of rash in erlotinib-treated lung cancer patients was … ,
fluorescence in situ hybridisation (FISH) analysis, DNA microarrays or proteomics? In summary, …

… paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib
in … At the time of writing this article a cost–benefit analysis for treatment with erlotinib has not …

… In multivariate analysis, survival after treatment with erlotinib was not influenced by the …
benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer, we …

… In the Phase I study of erlotinib in combination with carboplatin and paclitaxel, encouraging
activity was observed in patients with non-small cell lung cancer (NSCLC): two patients had …

… This review summarizes the results of recent clinical trials with these tyrosine kinase … of
erlotinib (Table 1). The subgroup analysis showed that the likelihood of a response to erlotinib …

… This systematic review included Phase III randomized clinical trials that compared single
agent erlotinib to … Random effects meta-analysis was used to pool outcomes across studies. …

… This is an up-to-date review of the clinical and economic impact of erlotinib for advanced
non-small-cell lung cancer. Overall, the studies found that erlotinib, compared with available …

… In this analysis, the contribution of gefitinib to the overall … erlotinib. This may be a result of
the larger proportion of patients enrolled in gefitinib trials (61% of all patients in the analysis) …

… -cell lung cancer (NSCLC) is the leading cause of cancer-… -TKI), such as erlotinib or gefitinib,
demonstrated efficacy in … In this article, the authors analyzed data of erlotinib in NSCLC…